MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
29. August 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
07. August 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
10. Juli 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., July 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in Jefferies Healthcare Conference
24. Mai 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in May Investor Conferences
08. Mai 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., May 08, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
10. April 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07. März 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
24. Januar 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
05. Januar 2023 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
14. November 2022 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...